Jazz Pharma Files for FDA Approval of a New Narcolepsy Drug

Jazz Pharma Files for FDA Approval of a New Narcolepsy Drug

Source: 
Motley Fool
snippet: 

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has submitted an application for Food and Drug Administration (FDA) approval of JZP-258, a new drug for cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy age 7 and up. To speed along an FDA review of JZP-258, the company is redeeming a priority review voucher that shortens the FDA's decision timeline from 10 months to six months.